National Comprehensive Cancer Network

About NCCN

NCCN Flash Update: NCCN Templates®

NCCN has published updates to the NCCN Chemotherapy Order Templates (NCCN Templates®) for Kidney Cancer to reflect the currently published NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Kidney Cancer, Version 1.2018.

  • The following NEW NCCN Templates® have been published:
    • KDN20 – Cabozantinib
    • KDN21 – Gemcitabine/CISplatin
    • KDN22 – Lenvatinib/Everolimus
    • KDN23 – Gemcitabine/SUNItinib
    • KDN24 – Nivolumab
    • KDN25 – Bevacizumab
    • KDN26 – Bevacizumab/Erlotinib
    • KDN27 – Bevacizumab/Everolimus

 

  • Indications for the following NCCN Templates have been updated:
    • KDN1 – Erlotinib
    • KDN2 – Bevacizumab
    • KDN4 – DOXOrubicin/Gemcitabine
    • KDN5 – Gemcitabine/CARBOplatin
    • KDN6 – PACLitaxel/CARBOplatin
    • KDN8 – SORAfenib
    • KDN9 – SUNItinib
    • KDN10 – Temsirolimus
    • KDN11 – High-Dose Aldesleukin (Interleukin-2)
    • KDN14 – Bevacizumab/Interferon alfa-2b
    • KDN17 – Everolimus
    • KDN18 – PAZOPanib
    • KDN19 – Axitinib

 

  • Cycle and/or regimen information for the following NCCN Templates have been reformatted to include precise cycle length and days of administration:
    • KDN1 – Erlotinib
    • KDN2 – Bevacizumab
    • KDN8 – SORAfenib
    • KDN9 – SUNItinib
    • KDN10 – Temsirolimus
    • KDN14 – Bevacizumab/Interferon alfa-2b
    • KDN17 – Everolimus
    • KDN18 – PAZOPanib
    • KDN19 – Axitinib

 

  • References for the following NCCN Templates have been updated:
    • KDN9 – SUNItinib
    • KDN18 – PAZOPanib
    • KDN19 – Axitinib

 

  • Serum glucose and hypertension monitoring recommendations in the Monitoring and Hold Parameters section for the following NCCN Template has been updated:
    • KDN9 – SUNItinib

 

  • Renal function monitoring recommendations in the Monitoring and Hold Parameters section for the following NCCN Template has been updated:
    • KDN11 – High-Dose Aldesleukin (Interleukin-2)

 

  • Emetic Risk in the NCCN Supportive Care section for the following NCCN Templates have been updated:
    • KDN1 – Erlotinib
    • KDN14 – Bevacizumab/Interferon alfa-2b

 

For the complete updated versions of the NCCN Guidelines®, NCCN Guidelines with NCCN Evidence Blocks™, the NCCN Drugs & Biologics Compendium (NCCN Compendium®), the NCCN Biomarkers Compendium®, the NCCN Chemotherapy Order Templates (NCCN Templates®), and the NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC™), please visit NCCN.org.

To view the NCCN Guidelines for Patients®, please visit NCCN.com/patients.

Free NCCN Guidelines apps for iPhone, iPad, and Android tablets are now available! Visit NCCN.org/apps

About NCCN Flash Updates™ 
NCCN Flash Updates™ is a subscription service from NCCN that provides timely notification of updated and new information appearing in the NCCN Guidelines, the NCCN Compendium®, and other NCCN Content. 

Subscribe to NCCN Flash Updates™ 

National Comprehensive Cancer Network® (NCCN®)

275 Commerce Drive, Suite 300
Fort Washington, PA 19034
Telephone: +1 215.690.0300 Fax: +1 215.690.0280 

Access information on permissions and licensing of NCCN Content  

© 2017 National Comprehensive Cancer Network. All Rights Reserved.